Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentazocine + naloxone is an oral combination analgesic used for the management of moderate to severe pain when alternative treatments are inadequate. It contains two active ingredients:\n- **Pentazocine** is a partial opioid agonist that acts on opioid receptors in the brain and nervous system to alter pain perception, providing analgesia.\n- **Naloxone** is an opioid antagonist included at a low dose (0.5 mg per tablet) that has no significant effect when taken orally but blocks opioid effects if the medication is misused by injection, thereby deterring abuse.\n\nThe combination provides effective pain relief while reducing the risk of misuse associated with opioids. The typical formulation contains 50 mg pentazocine and 0.5 mg naloxone per tablet[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pentazocine + naloxone.